Sophie Van Welden

Dr. Sophie Van Welden

Department of Internal Medicine and Pediatrics, Ghent University, Belgium
+2
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2017 in Applied and Environmental Microbiology
Verified
Journal Article
Open access
PDF file
LBLien Van Den Bossche
Lien Van Den Bossche
PHPieter Hindryckx
Pieter Hindryckx
Lindsey DevisscherLindsey Devisscher
Lindsey Devisscher
SDSarah Devriese
Sarah Devriese
SWSophie Van Welden
Sophie Van Welden
DLDebby Laukens
Debby Laukens
The promising results seen in studies of secondary bile acids in experimental colitis suggest that they may represent an attractive and safe class of drugs for the treatment of inflammatory bowel diseases (IBD). However, the exact mechanism by which bile acid therapy confers protection from colitogenesis is currently unknown. Since the gut microbiota plays a crucial role in the pathogenesis of IBD, and exogenous bile acid administration may affect the community structure of the microbiota, we examined the impact of the secondary bile acid ursodeoxycholic acid (UDCA) and its taurine or glycine conjugates on the fecal microbial community structure during experimental colitis. Daily oral administration of UDCA, tauroursodeoxycholic acid (TUDCA), or glycoursodeoxycholic acid (GUDCA) equally lowered the severity of dextran sodium sulfate-induced colitis in mice, as evidenced by reduced body weight loss, colonic shortening, and expression of inflammatory cytokines. Illumina sequencing demonstrated that bile acid therapy during colitis did not restore fecal bacterial richness and diversity. However, bile acid therapy normalized the colitis-associated increased ratio of Firmicutes to Bacteroidetes . Interestingly, administration of bile acids prevented the loss of Clostridium cluster XIVa and increased the abundance of Akkermansia muciniphila , bacterial species known to be particularly decreased in IBD patients. We conclude that UDCA, which is an FDA-approved drug for cholestatic liver disorders, could be an attractive treatment option to reduce dysbiosis and ameliorate inflammation in human IBD. IMPORTANCE Secondary bile acids are emerging as attractive candidates for the treatment of inflammatory bowel disease. Although bile acids may affect the intestinal microbial community structure, which significantly contributes to the course of these inflammatory disorders, the impact of bile acid therapy on the fecal microbiota during colitis has not yet been considered. Here, we studied the alterations in the fecal microbial abundance in colitic mice following the administration of secondary bile acids. Our results show that secondary bile acids reduce the severity of colitis and ameliorate colitis-associated fecal dysbiosis at the phylum level. This study indicates that secondary bile acids might act as a safe and effective drug for inflammatory bowel disease.

1 October 2017 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
THTom Holvoet
Tom Holvoet
SDSarah Devriese
Sarah Devriese
KCKarolien Castermans
Karolien Castermans
SBSandro Boland
Sandro Boland
DLDirk Leysen
Dirk Leysen
DLDebby Laukens
Debby Laukens

30 August 2017 in Nature Reviews Gastroenterology & Hepatology
Verified
Journal Article
Closed access
SWSophie Van Welden
Sophie Van Welden
ASAndrew C. Selfridge
Andrew C. Selfridge
PHPieter Hindryckx
Pieter Hindryckx

6 March 2017 in Histochemistry and Cell Biology
Verified
Journal Article
Closed access
PDF file
SDSarah Devriese
Sarah Devriese
LBLien Van Den Bossche
Lien Van Den Bossche
SWSophie Van Welden
Sophie Van Welden
THTom Holvoet
Tom Holvoet
IPIris Pinheiro
Iris Pinheiro
DLDebby Laukens
Debby Laukens

1 May 2017 in Laboratory Investigation
Verified
Journal Article
Open access
PDF file
LBLien Van Den Bossche
Lien Van Den Bossche
DBDaniel Borsboom
Daniel Borsboom
SDSarah Devriese
Sarah Devriese
SWSophie Van Welden
Sophie Van Welden
THTom Holvoet
Tom Holvoet
DLDebby Laukens
Debby Laukens
Bile acids regulate the expression of intestinal bile acid transporters and are natural ligands for nuclear receptors controlling inflammation. Accumulating evidence suggests that signaling through these receptors is impaired in inflammatory bowel disease. We investigated whether tauroursodeoxycholic acid (TUDCA), a secondary bile acid with cytoprotective properties, regulates ileal nuclear receptor and bile acid transporter expression and assessed its therapeutic potential in an experimental model of Crohn’s disease (CD). Gene expression of the nuclear receptors farnesoid X receptor, pregnane X receptor and vitamin D receptor and the bile acid transporters apical sodium-dependent bile acid transporter and organic solute transporter α and β was analyzed in Caco-2 cell monolayers exposed to tumor necrosis factor (TNF)α, in ileal tissue of TNFΔARE/WT mice and in inflamed ileal biopsies from CD patients by quantitative real-time polymerase chain reaction. TNFΔARE/WT mice and wild-type littermates were treated with TUDCA or placebo for 11 weeks and ileal histopathology and expression of the aforementioned genes were determined. Exposing Caco-2 cell monolayers to TNFα impaired the mRNA expression of nuclear receptors and bile acid transporters, whereas co-incubation with TUDCA antagonized their downregulation. TNFΔARE/WT mice displayed altered ileal bile acid homeostasis that mimicked the situation in human CD ileitis. Administration of TUDCA attenuated ileitis and alleviated the downregulation of nuclear receptors and bile acid transporters in these mice. These results show that TUDCA protects bile acid homeostasis under inflammatory conditions and suppresses CD-like ileitis. Together with previous observations showing similar efficacy in experimental colitis, we conclude that TUDCA could be a promising therapeutic agent for inflammatory bowel disease, warranting a clinical trial.

27 January 2017 in The Journal of Pathology
Verified
Journal Article
Closed access
PDF file
SWSophie Van Welden
Sophie Van Welden
MVMartine De Vos
Martine De Vos
Ben WielockxBen Wielockx
Ben Wielockx
STSimon J Tavernier
Simon J Tavernier
MDMelissa Dullaers
Melissa Dullaers
Pieter HindryckxPieter Hindryckx
Pieter Hindryckx